M E Juweid

Summary

Affiliation: University of Iowa
Country: USA

Publications

  1. ncbi 111In-pentetreotide versus bone scintigraphy in the detection of bony metastases of neuroblastoma
    M E Juweid
    Division of Nuclear Medicine, Department of Radiology, University of Iowa Hospitals and Clinics, Iowa City, IA, USA
    Nucl Med Commun 23:983-9. 2002
  2. ncbi 18F-FDG PET as a routine test for posttherapy assessment of Hodgkin's disease and aggressive non-Hodgkin's lymphoma: where is the evidence?
    Malik E Juweid
    University of Iowa, Iowa City, Iowa 52242 1077, USA
    J Nucl Med 49:9-12. 2008
  3. ncbi Peripheral T-cell lymphomas: variably or routinely fluorodeoxyglucose-avid?
    Malik E Juweid
    Division of Nuclear Medicine, Department of Radiology, University of Iowa, Iowa City, IA 52242, USA
    Leuk Lymphoma 48:1465-7. 2007
  4. ncbi Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma
    Malik E Juweid
    Department of Radiology, University of Iowa, Iowa City, IA 52242, USA
    J Clin Oncol 25:571-8. 2007
  5. ncbi FDG-PET/CT in lymphoma
    Malik E Juweid
    Department of Radiology and the Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USA
    Methods Mol Biol 727:1-19. 2011
  6. ncbi Positron-emission tomography and assessment of cancer therapy
    Malik E Juweid
    Department of Radiology and the Holden Comprehensive Cancer Center, University of Iowa, Iowa City 52242, USA
    N Engl J Med 354:496-507. 2006
  7. ncbi Technology evaluation: epratuzumab, Immunomedics/Amgen
    Malik Juweid
    Division of Nuclear Medicine, Department of Radiology, University of Iowa Hospitals and Clinics, Iowa City, IA 52242, USA
    Curr Opin Mol Ther 5:192-8. 2003
  8. ncbi Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography
    Malik E Juweid
    Department of Radiology, Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA 52242, USA
    J Clin Oncol 23:4652-61. 2005
  9. ncbi Radioimmunotherapy of B-cell non-Hodgkin's lymphoma: from clinical trials to clinical practice
    Malik E Juweid
    Division of Nuclear Medicine, Department of Radiology, University of Iowa Hospitals and Clinics, Iowa City 52242, USA
    J Nucl Med 43:1507-29. 2002
  10. ncbi Modeling combined radiopharmaceutical therapy: a linear optimization framework
    Ian M Besse
    Applied Mathematical and Computational Sciences, University of Iowa, Iowa City, IA, USA
    Technol Cancer Res Treat 8:51-60. 2009

Detail Information

Publications18

  1. ncbi 111In-pentetreotide versus bone scintigraphy in the detection of bony metastases of neuroblastoma
    M E Juweid
    Division of Nuclear Medicine, Department of Radiology, University of Iowa Hospitals and Clinics, Iowa City, IA, USA
    Nucl Med Commun 23:983-9. 2002
    ..In patients with similarly positive BS, PS might still provide unique prognostic information beyond that provided by BS. Further studies are therefore warranted...
  2. ncbi 18F-FDG PET as a routine test for posttherapy assessment of Hodgkin's disease and aggressive non-Hodgkin's lymphoma: where is the evidence?
    Malik E Juweid
    University of Iowa, Iowa City, Iowa 52242 1077, USA
    J Nucl Med 49:9-12. 2008
  3. ncbi Peripheral T-cell lymphomas: variably or routinely fluorodeoxyglucose-avid?
    Malik E Juweid
    Division of Nuclear Medicine, Department of Radiology, University of Iowa, Iowa City, IA 52242, USA
    Leuk Lymphoma 48:1465-7. 2007
  4. ncbi Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma
    Malik E Juweid
    Department of Radiology, University of Iowa, Iowa City, IA 52242, USA
    J Clin Oncol 25:571-8. 2007
    ..To develop guidelines for performing and interpreting positron emission tomography (PET) imaging for treatment assessment in patients with lymphoma both in clinical practice and in clinical trials...
  5. ncbi FDG-PET/CT in lymphoma
    Malik E Juweid
    Department of Radiology and the Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USA
    Methods Mol Biol 727:1-19. 2011
    ..Other promising molecular probes for lymphoma imaging will also be briefly discussed...
  6. ncbi Positron-emission tomography and assessment of cancer therapy
    Malik E Juweid
    Department of Radiology and the Holden Comprehensive Cancer Center, University of Iowa, Iowa City 52242, USA
    N Engl J Med 354:496-507. 2006
  7. ncbi Technology evaluation: epratuzumab, Immunomedics/Amgen
    Malik Juweid
    Division of Nuclear Medicine, Department of Radiology, University of Iowa Hospitals and Clinics, Iowa City, IA 52242, USA
    Curr Opin Mol Ther 5:192-8. 2003
    ..By January 2003, epratuzumab had received Orphan Drug status in the US for its potential in the treatment of NHL...
  8. ncbi Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography
    Malik E Juweid
    Department of Radiology, Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA 52242, USA
    J Clin Oncol 23:4652-61. 2005
    ....
  9. ncbi Radioimmunotherapy of B-cell non-Hodgkin's lymphoma: from clinical trials to clinical practice
    Malik E Juweid
    Division of Nuclear Medicine, Department of Radiology, University of Iowa Hospitals and Clinics, Iowa City 52242, USA
    J Nucl Med 43:1507-29. 2002
    ..This article provides both investigative and clinical nuclear medicine physicians with a better understanding of RIT capabilities and limitations in B-cell NHL and their role as consultants in the care of NHL patients...
  10. ncbi Modeling combined radiopharmaceutical therapy: a linear optimization framework
    Ian M Besse
    Applied Mathematical and Computational Sciences, University of Iowa, Iowa City, IA, USA
    Technol Cancer Res Treat 8:51-60. 2009
    ..We also consider extensions of this model to include an arbitrary number of independent radiopharmaceuticals and/or other treatment factors...
  11. ncbi Potential increased tumor-dose delivery with combined 131I-MIBG and 90Y-DOTATOC treatment in neuroendocrine tumors: a theoretic model
    Mark T Madsen
    Department of Radiology, University of Iowa, 200 Hawkins Dr, Iowa City, 52242, USA
    J Nucl Med 47:660-7. 2006
    ..In this paper, we investigate the conditions in which combined-agent therapy is advantageous and we quantify the expected tumor-dose gain...
  12. ncbi Scintigraphic detection of benign struma ovarii in a hyperthyroid patient
    Twyla B Bartel
    Department of Radiology, PET Center, University of Iowa Hospitals and Clinics, 200 Hawkins Drive, Iowa City, Iowa 52242
    J Clin Endocrinol Metab 90:3771-2. 2005
  13. ncbi Corn oil emulsion: a simple cholecystagogue for diagnosis of chronic acalculous cholecystitis
    Twyla B Bartel
    Division of Nuclear Medicine, Department of Radiology, University of Iowa Hospitals and Clinics, 200 Hawkins Dr, Iowa City, IA 52242, USA
    J Nucl Med 46:67-74. 2005
    ..This study investigated the use of a corn oil emulsion as an inexpensive alternative to sincalide in the scintigraphic diagnosis of chronic acalculous cholecystitis (CAC)...
  14. ncbi Radioimmunotherapy with 131I-rituximab: what we know and what we don't know
    Malik E Juweid
    Cancer Biother Radiopharm 18:489-95. 2003
  15. ncbi Revised response criteria for malignant lymphoma
    Bruce D Cheson
    Division of Hematology Oncology, Georgetown University Hospital, Washington, DC, USA
    J Clin Oncol 25:579-86. 2007
    ..Standardized response criteria are needed to interpret and compare clinical trials and for approval of new therapeutic agents by regulatory agencies...
  16. ncbi The role of FDG-PET scans in patients with lymphoma
    Pamela Seam
    National Cancer Institute, Bethesda, MD, USA
    Blood 110:3507-16. 2007
    ..Recent attempts to standardize PET in clinical trials and incorporation of this technology into uniformly adopted response criteria will hopefully lead to improved outcome for patients with lymphoma...
  17. ncbi Imaging bone and soft tissue tumors with the proliferation marker [18F]fluorodeoxythymidine
    Andreas K Buck
    Department of Nuclear Medicine, Technische Universitat Munchen, Munich, Germany
    Clin Cancer Res 14:2970-7. 2008
    ....
  18. ncbi Role of positron emission tomography in lymphoma
    Malik E Juweid
    J Clin Oncol 23:4577-80. 2005